Raymond James analyst Ryan Deschner upgraded Dianthus (DNTH) to Strong Buy from Outperform with a price target of $123, up from $63. The firm is “increasingly bullish” on claseprubart following the Q4 update. The analyst increased the drug’s probability of success in chronic inflammatory demyelinating polyneuropathy to 80% citing the additional validation and progress of claseprubart in the Phase 3 CAPTIVATE CIDP pivotal study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks
- Dianthus price target raised to $130 from $100 at Clear Street
- Dianthus announces $400M common stock offering
- Dianthus price target raised to $98 from $81 at Jefferies
- Dianthus price target raised to $132 from $67 at Baird